Personalized exosome therapy: why responses vary and what biomarkers could add
Why response to exosomes appears to vary between individuals, how disease stage may matter, and what predictive biomarkers are meant to do.

Key takeaways.
- Response to exosome therapy appears to vary widely, though clinical data are limited.
- Reports describe a spread from marked improvement to no detectable benefit.
- Disease stage is the most obvious candidate factor, with earlier disease the more plausible setting.
- Predictive biomarkers are pre-treatment measurements that forecast the likelihood of response.
- Predictive biomarkers differ from prognostic and pharmacodynamic biomarkers.
- Exosomes are not FDA-approved for therapeutic use, and personalization is still a research goal.
Responses appear to vary
Precision medicine means tailoring treatment to the individual instead of applying one protocol to everyone. It is most advanced in oncology and is now being discussed for biologics.
For exosomes, the picture comes from case series, pilot trial reports and anecdotal experience, so it is not well characterized. The reported pattern resembles other biologics. Some individuals are described as improving markedly, a larger group moderately, and others little or not at all.
Why disease stage may matter
Disease stage is the most obvious candidate explanation. The biological reasoning is that the proposed mechanisms need target cells that can still respond.
In osteoarthritis, for example, early disease with preserved cartilage is thought to be a more plausible setting than end-stage disease where cartilage is gone. This is a rationale, not a demonstrated result.
What predictive biomarkers are for
A predictive biomarker is a measurement taken before treatment that forecasts how likely an individual is to respond. In trials, such markers could enrich for likely responders and spare others unnecessary exposure.
Two related terms mean different things. A prognostic biomarker predicts the course of disease regardless of treatment. A pharmacodynamic biomarker shows that a treatment engaged its target, without necessarily predicting benefit.
Where this stands
Personalization of exosome therapy is a research direction, not current practice. Validated predictive biomarkers would require far more clinical data than exist today.
Exosome therapies are not FDA-approved for therapeutic use.
Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- Autologous versus allogeneic approaches
- Biomarker-guided selection strategies
- Exosome engineering for targeted delivery
- Applying precision medicine principles in practice
Common questions.
Why do some patients respond to exosomes and others do not?
What is a predictive biomarker?
Sources
- Murphy, D. E., et al. (2019). Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Experimental & Molecular Medicine, 51, 1-12.
- Wiklander, O. P. B., et al. (2015). Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of Extracellular Vesicles, 4, 26316.
Keep reading.
Exosome · 3 min read
Ethics of offering exosome therapy: consent, cost and marketing
The ethical ground rules for clinicians considering exosomes: informed consent for an investigational therapy, patient selection, cost, honest marketing and competency.
Start the lessonExosome · 3 min read
What are exosomes?
Exosomes are nanoscale vesicles that cells release to carry proteins, RNA and lipids to other cells. Here is what they are, how they form and where they stand with the FDA.
Start the lessonExosome · 3 min read
How were exosomes discovered?
Exosomes were first seen in 1983 and dismissed as cell waste for over a decade. Two later findings changed that view and shaped the questions the field still asks.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.